Clinical trial
A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration
NCT02305238 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration
- Lead sponsor
- Bayer
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 19, 2014
- Completion date
- December 20, 2017
- Enrollment
- 288 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.